Therapy for atopic dermatitis (AD), a chronic inflammatory skin disease that usually starts in infancy or early childhood, entered the specialty pharmacy space over the past two years with the approval of dupilumab (Dupixent, sanofi-aventis), an injectable biologic approved in March 2017 for adults with moderate to severe AD and, as of March 2019, for adolescents aged 12 to 17 years with moderate to severe AD. Dupilumab is still being studied in the younger pediatric population.
But